Eurand Receives a Notice of Allowance for U.S. Patent Application Covering Amrix

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

DAYTON, Ohio, April 9, 2008 (PRIME NEWSWIRE) -- Eurand N.V.
(Nasdaq:EURX), a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies, announced today that the United States Patent and
Trademark Office (USPTO) has issued a notice of allowance for U.S.
patent application No. 10/713,929, entitled "Modified Release Dosage
Forms of Skeletal Muscle Relaxants." Eurand's patent application was
filed November 14, 2003 and includes allowed claims covering
Amrix(r), a product currently marketed in the U.S. by Cephalon under
license from Eurand. Amrix is the only approved once-daily
formulation of the skeletal muscle relaxant, cyclobenzaprine
hydrochloride, for the relief of muscle spasm associated with acute,
painful musculoskeletal conditions.

Gearoid Faherty, Chief Executive Officer of Eurand, commented, "We
are pleased to receive this notice of allowance. Eurand seeks to
protect all of its proprietary technologies, and we have accumulated
a significant portfolio. This application is a particularly
meaningful addition for us, however, because of our relationship with
Cephalon."

About Amrix(r)

Amrix(r) (Cyclobenzaprine Hydrocholoride) is the first and only
FDA-approved once-daily, extended release skeletal muscle relaxant
that is indicated as an adjunct to rest and physical therapy for the
relief of muscle spasm associated with acute, painful musculoskeletal
conditions. The product is available in 15 and 30 mg dosage
strengths. Eurand developed Amrix using its proprietary Diffucaps(r)
technology, which permits once-daily dosing (unlike other muscle
relaxants which are dosed 3-4 times per day). Eurand has out-licensed
North American marketing rights to Cephalon, while it retains
ex-North American marketing rights. According to IMS, Cyclobenzaprine
HCl is the most widely prescribed muscle relaxant in the U.S.,
representing 37 percent of the 45 million prescriptions written for
muscle relaxants in 2006.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand has
completed two phase III clinical trials on its lead product
candidate, Zentase(tm), intended for the treatment of Exocrine
Pancreatic Insufficiency and has submitted an NDA for this product.
Eurand's technology platforms include bioavailability enhancement of
poorly soluble drugs, customized release,
taste-masking/fast-dissolving formulations and drug conjugation.

Eurand is a global company with facilities in the USA and Europe. For
more information, visit Eurand's website at www.eurand.com.

This release, and oral statements made with respect to information
contained in this release, constitutes forward-looking statements.
Such forward-looking statements include those which express plan,
anticipation, intent, contingency, goals, targets or future
development and/or otherwise are not statements of historical fact
including, but not limited to our plans for our NDA filing,
enrollment and future plans for our clinical trials, progress of and
reports of results from clinical studies, clinical development plans
and product development activities. The words "potentially", "could",
"calls for" and similar expressions also identify forward-looking
statements. These statements are based upon management's current
expectations and are subject to risks and uncertainties, known and
unknown, which could cause actual results and developments to differ
materially from those expressed or implied in such statements.
Factors that could affect actual results include risks associated
with the possibility that the FDA refuses to approve our NDA; the
outcome of any discussions with the FDA; and unexpected delays in
preparation of materials for submission to the FDA as a part of our
NDA filing. Forward-looking statements contained in this press
release are made as of this date, and we undertake no obligation to
publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise. Actual events could
differ materially from those anticipated in the forward-looking
statements.

CONTACT: Eurand N.V.
Mario Crovetto, Chief Financial Officer
+39 02 95428 521
mario.crovetto@eurand.com

The Ruth Group
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
Elizabeth Scott
646-536-7014
escott@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;